Labcorp, a global leader of innovative and comprehensive laboratory services, announces it has finalized its acquisition of select outreach laboratory services from Ballad Health. The sale of these lab services, combined with Ballad Health’s ongoing strategic relationship with Labcorp, aims to enhance patient care, expand access to advanced testing and improve efficiency for the health system and its patients.

South Korean diagnostic firm Noul said Wednesday that it has inked an agreement to launch its hematology and malaria testing tools in Europe through German lab chain Limbach Group.

On 5 December, Lei Haichao, Director General of China's National Health Commission (NHC), met with Saudi Health Minister Fahad Abdulrahman AlJalajel in Beijing for an in-depth discussion on enhancing bilateral health cooperation.

Akoya Biosciences on Tuesday said it has inked an exclusive global license agreement with German molecular diagnostics firm NeraCare to develop and commercialize NeraCare’s Immunoprint test for early-stage melanoma on Akoya's immunofluorescence platform.

A. Menarini Diagnostics announces an exclusive Distribution Agreement with Sinocare to register, promote, distribute, and market a new Sinocare 3rd Generation Continuous Glucose Monitoring (CGM) System within reimbursed markets. This landmark agreement grants A. Menarini Diagnostics exclusive rights to introduce this health technology to more than 20 jurisdictions in Europe.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The Egypt Healthcare Authority (EHA), Roche Diagnostics and Roche Pharmaceuticals have signed a memorandum of understanding (MOU) to advance digital pathology in Egypt.

Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a new collaboration with UK Biobank to create the world’s first comprehensive, large-scale epigenetic dataset. The project will utilise Oxford Nanopore’s information-rich DNA/RNA sequencing technology to map the epigenome of 50,000 participant samples to unlock crucial insights into disease mechanisms, with the aim of improving patient outcomes. This publicly available data will serve as a unique resource for the scientific community, bringing new opportunities to advance our understanding of genomics.

Xcell Therapeutics is expanding the business scope of its exosome isolation and purification device, “EXODUS,” into the diagnostics market.

Artificial intelligence continues to reshape healthcare, but a new study highlights the challenges of integrating AI tools into medical practice. ChatGPT-4, an AI chatbot developed by OpenAI, outperformed doctors in a diagnostic accuracy study, raising questions about how effectively physicians can use such technology.